associations between patient symptom clusters, medical and surgical treatments, and baseline factors.
INTRODUCTION AND OBJECTIVES:
The degree of bother attributed to lower urinary tract symptoms (LUTS) drives care seeking and treatment aggressiveness. The longitudinal correlation of symptom severity and bother, however, is not well understood. In this study, we conducted a longitudinal evaluation of the correlation between symptom severity and bother in men and women seeking care for LUTS.
METHODS: Men and women with LUTS seeking care at 6 tertiary care centers were enrolled in The Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Observational Cohort Study. Participants completed the LUTS Tool questionnaire, which includes 22 questions that evaluate an individual's LUTS symptom severity and bother. Polychoric correlations between symptom severity and bother were calculated for all 22 symptoms at baseline, 3 and 12 months. Repeated measures linear regression models were used to assess differences in correlations between males and females, and over time.
RESULTS: 519 men and 545 women reported on their symptoms at any of the three time points. There were no racial or ethnic differences between men and women (p-value[0.620 and 0.907, respectively) . Men were older than women (61.2 vs 56.4, p-value<0.001). The LUTS symptoms associated with highest correlations between severity and bother (!0.80 for at least two time points) were incomplete emptying, urgency, urgency with fear of leakage and bladder pain. Those with lowest correlations ( 0.65 for at least two time points) were daytime frequency, nocturia, splitting or spraying, urinary incontinence (UI) while sleeping and UI for no reason [ Figure 1 ]. Correlations between severity and bother in men and women were largely similar, with the exception of higher correlations for frequency, nocturia, incomplete emptying, hesitancy and straining symptoms in women and higher correlation for UI during sex in men. Correlations between severity and bother for UI and urgency incontinence symptoms increased over time, while correlations for straining symptoms decreased over time.
CONCLUSIONS: The relationship between LUTS severity and bother is complex, and effective treatments should improve both. Individual LUTS severity and bother values correlate highly but not perfectly. In most situations (including clinical care), measurement of both is likely redundant.
healthier older persons. Chronic inflammation is assumed to play a role in lower urinary tract symptoms, however is association with urinary leakage in both men and women has not been assessed. Our objective was to determine if serum markers for inflammation (e.g. C-reactive protein (CRP) and interleukin-6 (IL-6)) were associated with urinary leakage in older Americans.
METHODS: Health ABC is a longitudinal cohort consisting of 3,075 healthy men and women, aged 70-79 at baseline; 45 percent of the women and 33 percent of the men are African-American. Serum CRP and IL-6 were measured in year 2 and urinary health questionnaires were administered in years 1, 4, and 11. Baseline distributions of demographic characteristics and urinary leakage frequency were examined according to quartiles of CRP and IL-6. Analysis was conducted on the 2,774 subjects with CRP and 2,736 subjects with IL-6 levels measured for associations with urinary outcomes using ordinal logistic regression.
RESULTS: Overall, 21.1% and 28.0% of participants reported daily urinary leakage episodes in year 4 and year 11, respectively. The prevalence of daily leakage was higher for participants in the highest quartile of CRP as for those in the lowest quartile in both years; the same was observed for IL-6. A one unit increase in log IL-6 was associated with 1.25 greater odds (95% CI: 1.07-1.46) of more frequent leakage episodes in year 4. Similar findings were observed for CRP (OR[1.13, 95% CI: 1.03-1.24). Urinary leakage was also more frequent with higher CRP and IL-6.
CONCLUSIONS: Results of this population-based study show a consistent association of higher CRP or IL-6 levels with urinary leakage in both men and women. These results support the hypothesized role of inflammation in the development of urinary incontinence outside of Benign Prostate Hyperplasia or Overactive Bladder, and a possible role for anti-inflammatory agents in its treatment.
Source of Funding: This research was supported by the Aikens Center for Neurology Research and the National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459. This research was funded in part by the Intramural Research Program of the NIH, National Institute on Aging.
PD31-12 MIRABEGRON AND THE RISK OF ARRHYTHMIAS: A POPULATION-BASED COHORT STUDY
Rano Matta*, Simon Greaves, David Juurlink, Muhammad Mamdani, Tara Gomes, Mina Tadrous, Toronto, Canada INTRODUCTION AND OBJECTIVES: Mirabegron, a b-3 adrenoreceptor agonist, used to treat overactive bladder (OAB) has been shown in clinical trials to produce a minor increase in resting heart rate, blood pressure, and QTc interval. More patients are being prescribed mirabegron, owing to its limited adverse effects relative to antimuscarinic OAB drugs. However, there is a lack of cardiovascular safety data in older patients and those with existing cardiovascular disease. We evaluated the risk of cardiac arrhythmias and other adverse cardiovascular events in older patients using mirabegron relative to other OAB agents.
METHODS: We conducted a population-based cohort study of patients !66 years old who were new users of OAB drugs between June 1, 2015 and March 31, 2017 in Ontario, Canada. We followed patients for one year after starting the medication or until they discontinued or switched treatment. The primary outcome was a composite of hospitilization or emergency room visit for arrhythmia and tachycardia events. The secondary outcome was myocardial infarction (MI) or stroke. Patients taking mirabegron were matched to subjects taking other OAB agents on age, sex, date of initiating medication, and a high dimensional propensity score. The primary analysis used Cox proportional hazards regression.
RESULTS: We matched 16,948 mirabegron users to 21,870 users of other OAB drugs. The median age of the cohort was 76 (Interquartile range 71-83), and most were female (N[25,189, 64.9%) . A large proportion of the cohort had hypertension (N[30,393, 78.3%) and diabetes (N[13,757, 35.4%) . Overall, 624 (1.6%) patients experienced an arrythmia or tachycardia event and 480 (1.2%) experienced an MI or stroke. The 1-year cumulative incidence of arrhythmia or tachycardia events was 3.3% in the mirabegron group and 3.5% in the other OAB drugs group ( INTRODUCTION AND OBJECTIVES: Long term outcomes of transobturator male sling evaluated according to baseline urinary incontinence severity has not been reported. We aim to present the longterm outcome of transobturator sling for male stress urinary incontinence clustered according to baseline urinary incontinence severity and further determine the predictors for durability of treatment success.
METHODS: After IRB approval, a non-concurrent study was performed on a prospectively maintained database for all males with stress urinary incontinence (SUI) who underwent transobturator sling at our institution from August 2006 to June 2012. Patient demographics and perioperative data such as co-morbidities, history of pelvic radiation, prior treatments, concomitant urge incontinence, concomitant procedure, and urodynamic (UDS) findings were extracted. Baseline SUI severity was clustered into mild ( 2 ppd), moderate (3-4 ppd) or severe (!5 ppd). The treatment outcomes such as post-treatment pads per day (ppd), outcome satisfaction and
